Dopaminergic agonist Ro 8-4650 in Parkinson's disease

Publisher Website
Google Scholar
Abstract
An isoquinoline derivative Ro 8-4650 (dl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-2-methylisoquinoline hydrochloride) with dopaminergic properties was studied in a randomized crossover trial. The group studied comprised 37 patients with idiopathic parkinsonism, not previously treated with levodopa or dopamine agonists. The trial drug was significantly more effective than placebo, but the clinical improvement, according to the Webster rating scale, was small. No significant difference was observed as regards involuntary movements, but the trial drug led to more frequent minor side-effects. The trial drug, despite its proven effect in Parkinson''s disease, has only limited clinical value.

This publication has 1 reference indexed in Scilit: